Trials / Conditions / Pigmented Villonodular Synovitis

Pigmented Villonodular Synovitis

12 registered clinical trials studyying Pigmented Villonodular Synovitis.

Status	Trial	Sponsor	Phase
Active Not Recruiting	Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER) NCT05804045	Abbisko Therapeutics Co, Ltd	Phase 3
Completed	A Study to Evaluate Safety and Efficacy of AMB-05X Injections in Subjects With TGCT NCT05349643	AmMax Bio, Inc.	Phase 2
Active Not Recruiting	Study of Vimseltinib for Tenosynovial Giant Cell Tumor NCT05059262	Deciphera Pharmaceuticals, LLC	Phase 3
Terminated	A Phase 2 Study of Intravenous AMB-05X in Tenosynovial Giant Cell Tumor Patients NCT04938180	AmMax Bio, Inc.	Phase 2
Completed	Screening of Specific Genes for Pigmented Villous Nodular Synovitis NCT04955535	Peking University Third Hospital	—
Active Not Recruiting	Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor NCT03069469	Deciphera Pharmaceuticals, LLC	Phase 1 / Phase 2
Completed	Study of Cabiralizumab in Patients With Pigmented Villonodular Synovitis / Diffuse Type Tenosynovial Giant Cel NCT02471716	Five Prime Therapeutics, Inc.	Phase 1 / Phase 2
Completed	Phase 3 Study of Pexidartinib for Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sh NCT02371369	Daiichi Sankyo	Phase 3
Completed	MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS) NCT01643850	Novartis Pharmaceuticals	Phase 2
Completed	Clinical Study of Magnetic Resonance Imaging and Deep Learning of Joint Synovial Disease NCT04952896	Peking University Third Hospital	—
Completed	Study of Nilotinib Efficacy in Pigmented Villo-Nodular Synovitis/ Tenosynovial Giant Cell Tumour (PVNS/TGCT) NCT01261429	Centre Leon Berard	Phase 2
Completed	Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tum NCT01207492	Andrew J. Wagner, MD, PhD	Phase 2